San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, MediPrint Ophthalmics is raising $4,999,999.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Dan Myers played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About MediPrint Ophthalmics
An emerging San Diego-based clinical stage eye care pharmaceutical company developing and commercializing a proprietary ocular drug delivery portfolio focused on glaucoma, dry eye and ocular allergy initially. We are using our proprietary MediPrint process to develop, clinically test and commercialize drug-eluting, comfort-enhancing contact lenses to treat millions of contact lens wearers worldwide, without the use of eye drops. We plan to address a variety of eye care unmet needs, all with extensive market opportunities. We aim to develop and commercialize a deep product pipeline, supported by strong intellectual property, with a highly experienced and successful execution team.

To learn more about MediPrint Ophthalmics, visit http://leolens.com/

Contact:
Dan Myers, President and Chief Executive Officer
858-385-0800
dmyers@leolens.com
https://www.linkedin.com/in/dan-myers-08a3a810/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved